Skip to content
Search

Latest Stories

ASOS revamps board amid efforts to revive business

BRITISH online fashion and cosmetic retailer ASOS Plc has revamped its board to name new directors on Wednesday (2).
The company appointed four new independent non-executive directors, including Ocado Solutions chief executive officer Luke Jensen, Sky executive Mai Fyfield, former Burberry executive Eugenia Ulasewicz, and Micro Focus executive Karen Geary.
With the latest appointments, the number of independent non-executive directors in the board increased to six.
Two existing directors, Hilary Riva and Rita Clifton, are scheduled to leave the fashion firm next year after their six-year tenures.
Jensen will be responsible for the audit and nomination committees, along with Geary and Ulasewicz, while Fyfield will oversee the audit and remuneration committees.
Adam Crozier, chairman, ASOS plc said: "On behalf of the board, I'd like to warmly welcome Karen, Luke, Mai and Eugenia to ASOS. Their world-class experience, skills, and expertise will be essential in guiding the business through the next stage of global growth, fuelled by the substantial investments it has made over the past few years. I'd also like to extend our thanks and gratitude to Hilary and Rita for the important role they have played in the development of ASOS and the board during their tenure."
According to ASOS, it sells more than 85,000 branded and ASOS brand products through localised app, mobile, and desktop web experiences, delivering from fulfilment centres in the US and Europe, including the UK.
ASOS is trying to get experienced executives to revive its business after the firm issued its third profit warning in July since last December.
The British firm said the overall sales climbed 12 per cent in the four months to June 30. However, growth in the US and Europe was lower than expected, at 12 per cent and 5 per cent, respectively, owing to operational failures.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less